NCBI PubMed Central
open access
Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.#969600
- Atezolizumab Plus Bevacizumab in First Line NSCLC Patients#879873
- Combination Therapy for BRAF-V600E Metastatic CRCm#1059781
- Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma#1088391
- Cost-effectiveness analysis of Sacituzumab Tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-Mutated advanced NSCLC in China#298348
Record · ID 404507
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive